by Cherry Salazar | Sep 22, 2025
Moderna, which led the biotechnology sector’s pandemic-driven surge, struggles to keep pace with the market. Moderna, Inc.’s windfall during the pandemic has now become its headwind. Once propelled to record highs by its breakthrough messenger RNA technology, the...
by Mariam Kiparoidze | Sep 28, 2023
Even though Covid-19 cases and hospitalization numbers are up, they won’t be a shot in the arm for either Moderna or Pfizer stock. Pfizer (NYSE:PFE) closed at $32.69 per share, down by 36.2% year to date on September 22. Moderna (Nasdaq:MRNA) ended the week on a...
by Suzannah Cavanaugh | Dec 16, 2020
This time last year, Moderna, Inc., was starting to look a lot like Theranos. Moderna had spent the large part of a decade selling investors on the idea of an unprecedented product—a messenger RNA drug. The company, valued at $7.5 billion, made history in December...
by Suzannah Cavanaugh | Oct 30, 2020
In the Covid-19 vaccine race, Moderna, Inc. made headlines last week for the representative diversity of its trial candidates. The company touted 37% enrollment by people of color in late-stage trials, a figure that nearly mirrors the 40% of the population U.S....
by Suzannah Cavanaugh | Oct 2, 2020
Moderna Inc. announced Tuesday that its Covid-19 vaccine candidate had generated levels of virus-neutralizing antibodies in older adults on par with those produced in younger trial participants, a crucial step towards approval. The early-stage result gives Moderna a...
